CalciMedica Inc. (NASDAQ:CALC) Stock Rated “Hold” by Wall Street Brokerages

CalciMedica Inc. (NASDAQ:CALC) has received a consensus recommendation of “Hold” from the five research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $50.00.

Several analysts recently commented on CALC shares. UBS Group reissued a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th. Weiss Ratings upgraded shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Guggenheim initiated coverage on shares of CalciMedica in a report on Thursday, August 20th. They set a “buy” rating on the stock. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Finally, Wall Street Zen downgraded shares of CalciMedica from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 12th.

Institutional Trading of CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Renaissance Technologies LLC lifted its holdings in shares of CalciMedica Inc. (NASDAQ:CALC) by 45.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 128,075 shares of the company’s stock after buying an additional 39,775 shares during the period. Renaissance Technologies LLC owned approximately 0.81% of CalciMedica worth $69,000 at the end of the most recent reporting period.

CalciMedica Price Performance

Shares of NASDAQ CALC opened at $1.12 on Friday. The company has a 50 day simple moving average of $2.27 and a two-hundred day simple moving average of $3.18. CalciMedica has a fifty-two week low of $1.08 and a fifty-two week high of $36.00. The company has a market capitalization of $7.65 million, a price-to-earnings ratio of -0.16 and a beta of 0.76. The company has a debt-to-equity ratio of 1.67, a quick ratio of 5.58 and a current ratio of 5.58.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.97. Analysts expect that CalciMedica will post -5.25 EPS for the current fiscal year.

CalciMedica Company Profile

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which play a role in the activation of immune cells and the inflammatory response.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being studied for acute and chronic inflammatory conditions, including severe acute pancreatitis and acute kidney injury associated with severe inflammatory illness.